Compare Invesco DB Agriculture Fund (DBA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Merck & Co., Inc. — how do they compare? Invesco DB Agriculture Fund trades at $27.6, while Merck & Co., Inc. trades at $121.82 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Invesco DB Agriculture Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| DBA | MRK | |
|---|---|---|
52-Week High | $28.73 | $129.52 |
52-Week Low | $25.44 | $77.60 |
Market Cap | — | $298.31B |
Sector | — | Health |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund) trades at $27.72, down 0.18% with a bullish technical signal supported by moving averages. The ETF tracks agricultural commodities including corn, soybeans, and livestock. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion U.S. crop purchase commitment through 2028, potentially benefiting agricultural ETFs.
The fund offers exposure to rising commodity prices driven by supply constraints and geopolitical factors, but faces volatility from weather patterns and global demand shifts. Key risks include commodity price fluctuations and concentrated agricultural exposure. Analyst sentiment is mixed with technical indicators showing strength but overbought conditions on shorter-term RSI.
Merck (MRK) trades at $124.03, up 0.4% on the day, with a bullish technical signal and strong analyst support. The company reported solid earnings beats in recent quarters, including Q1 2026's better-than-expected loss, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth efforts amid competitive pressures.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include patent expirations and rising debt. With a consensus price target of $137.30 offering ~11% upside, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic and regulatory headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
